COVID-19 -- Worldwide/Unknown
Importance: Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate disease is unknown.
Objective: To determine the efficacy of 5 or 10 days of remdesivir treatment compared with standard care on clinical status on day 11 after initiation of treatment.
Design, Setting, and Participants: Randomized, open-label trial of hospitalized patients with confirmed severe acute
Read more about it at HealthMap Global Disease Alerts via http://healthmap.org/ln.php?7707596&promed&0
No comments:
Post a Comment